![](/images/buts/heroes_alert_button.jpg)
Response Genetics, Inc.
Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer based on its technologies. The Company generates revenues primarily from sales of its analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. During the fiscal year ended December 31, 2008 (fiscal 2008), the Company launched its diagnostic tests under the brand name ResponseDx for non small cell lung cancer and colon cancer.Using its technologies, the Company extracts nucleic acids, such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE), specimens and analyze genetic information contained in these tissues. The Company generates clinically relevant information regarding the risks of recurrence of cancer or chemotherapy response using approximately 30,000 genes available from microarray profiling of FFPE specimens.
![](/images/buts/heroes_alert_button.jpg)
News
Australian stocks ended flat on Wednesday as shares gave up early gains in the afternoon dragged by banks. Miners advanced as investors were optimistic about the iron ore prices. At the close, the benchmark S&P/ASX200 index was up 1.6 points at 4925.9 points, while the broader All Ordinaries index lifted 7.7 points, or 0.15 per cent, to 4947.2 points.
###
42,700 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 12) (Last 30 Days: 66) (Since Published: 6561)